A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Abroad (travel likely)RecruitingPHASE1
Conditions
Multiple Myeloma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China
Tianjin Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin Municipality, China
The First Affiliated Hospital of Nanchang University, Nanchang, China
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China
Study leads
Clinical Trials
Study Director
Hoffmann-La Roche